Try our Advanced Search for more refined results

Federal Trade Commission et al v. Vyera Pharmaceuticals, LLC et al

  1. February 27, 2023

    FTC Pushes To Hold Shkreli In Contempt

    The Federal Trade Commission continued urging a New York federal court to hold convicted "pharma bro" Martin Shkreli in contempt for failing to comply with document requests in an investigation into accusations he violated an order banning him from working in the pharmaceutical industry.

  2. February 10, 2023

    Shkreli Says His New Co. Doesn't Violate FTC's Pharma Ban

    Convicted "Pharma Bro" Martin Shkreli opposed the Federal Trade Commission's contempt motion accusing him of failing to comply with an order banning him from working in the pharmaceutical industry, arguing that his new company Druglike Inc. is a software business, not a pharmaceutical company.

  3. January 20, 2023

    FTC Wants Shkreli Held In Contempt Over Stonewalling

    The Federal Trade Commission asked a New York federal judge on Friday to hold "Pharma Bro" Martin Shkreli in contempt for failing to turn over documents it said were essential to the agency's investigation into whether he violated an order banning him from working in the pharmaceutical industry.

  4. June 10, 2022

    States Get $853K In Pared Down Shkreli Antitrust Case Fees

    A New York federal judge signed off Friday on $853,440.80 in attorney fees for four of the states that successfully sued "pharma bro" Martin Shkreli for an anti-competitive scheme safeguarding a 40-fold price increase for a lifesaving drug, a significant reduction on the more than $2 million initially sought.

  5. April 26, 2022

    States In Shkreli FTC Trial Told To Redo $2.2M Atty Fee Ask

    Disgraced former pharmaceutical executive Martin Shkreli is on the hook for the attorney fees from states that joined in his antitrust trial, but they cannot get the $2.2 million they requested and must revise their calculation, a New York federal judge ruled Tuesday.

  6. April 25, 2022

    Shkreli Poses 'Serious Risk' Without Pharma Ban, Judge Says

    A New York federal judge denied Martin Shkreli's request to lift his lifetime ban from participating in the pharmaceutical industry while he appeals it, saying Monday that "there is a serious risk" he will reengage in anti-competitive conduct that will harm patients.

  7. April 12, 2022

    ​​​​​​​Duane Morris Says Shkreli Owes It $2M In Bid To Drop Client

    Duane Morris LLP is seeking to withdraw as Martin Shkreli's counsel in an antitrust case against the disgraced pharmaceutical executive, telling a New York federal court that the firm hasn't been paid since October and is owed more than $2 million, and that Shkreli is out of money.

  8. March 18, 2022

    Shkreli Can't Press Pause On $64M Antitrust Judgment

    Disgraced former pharmaceutical executive Martin Shkreli can't put off paying a $64.6 million antitrust judgment against him while he fights it in a higher court, a New York federal judge has ruled.

  9. March 15, 2022

    States Fight Shkreli's Bid To Pause Monetary Penalty

    Seven states that helped the Federal Trade Commission win an antitrust case against "pharma bro" Martin Shkreli are lining up to implore a New York federal judge not to allow him to put off paying the $64.6 million judgment against him while he appeals.

  10. March 08, 2022

    States Seek $2.2M In Atty Fees For Joining In Shkreli Case

    Four states that helped the Federal Trade Commission win an antitrust case against ex-pharma executive Martin Shkreli are asking a New York federal judge to award $2.2 million in attorney fees, saying the legal battle was complex and costly.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!